Stephen W Webster
CIK 1438421 · CHIEF FINANCIAL OFFICER · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.91M
Companies
11
Total Filings
66
Lifetime Open-Market Net
-$4.52M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NXTC | Director | — | $5.42 | — | $0 | 8 | 2026-06-22 |
| CGEM | Director | — | $17.47 | — | $0 | 6 | 2026-06-18 |
| ELOX | Director | — | $12.81 | — | $0 | 1 | 2026-06-10 |
| Gritstone bio, Inc. (GRTS) Delisted | Director | — | $0.03 | — | $0 | 2 | 2024-06-20 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | Director | — | $1.48 | — | $0 | 5 | 2023-06-01 |
| Nabriva Therapeutics plc (NBRV) Delisted | Director | 458 | $1.42 | $650 | $34.3K | 8 | 2022-08-04 |
| Viking Therapeutics, Inc. (VKTXW) Delisted | Director | 8,000 | $4.60 | $36.8K | $41.7K | 5 | 2020-01-03 |
| Spark Therapeutics, Inc. (ONCE) Delisted | CHIEF FINANCIAL OFFICER | 0 | — | — | -$4.60M | 15 | 2019-12-17 |
| VKTX | Director | — | $33.86 | — | $0 | 2 | 2016-01-06 |
| RPRX | SVP, Finance & CFO | 31,875 | $59.97 | $1.91M | $0 | 3 | 2010-09-13 |
| HEARUSA INC (EAR) Delisted | Director | — | $2.57 | — | $0 | 3 | 2010-06-14 |
Recent Filings · Page 2 of 7
66 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-23 | NXTC | Grant (A) | — | $0 | EDGAR |
| 2023-06-12 | CGEM | Grant (A) | — | $0 | EDGAR |
| 2023-06-01 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Disp (D) | — | $0 | EDGAR |
| 2022-12-19 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-08-04 | Nabriva Therapeutics plc (NBRV) Delisted | Sell (S) | −7,826 | -$1.5K | EDGAR |
| 2022-06-24 | NXTC | Grant (A) | — | $0 | EDGAR |
| 2022-06-23 | CGEM | Grant (A) | — | $0 | EDGAR |
| 2022-03-25 | CGEM | Grant (A) | — | $0 | EDGAR |
| 2021-12-10 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-08-04 | Nabriva Therapeutics plc (NBRV) Delisted | Sell (S) | −777 | -$932 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.